The Partners HealthCare Board of Directors has named Anne Klibanski, MD Interim President and Chief Executive Officer of Partners HealthCare. Dr. Klibanski will succeed Dr. David Torchiana, who has served since March 2015 and will retire at the end of April.
In her current role as Chief Academic Officer for Partners, a position she has held since 2012, Dr. Klibanski has leadership responsibilities spanning research, teaching and clinical activities. She leads multiple systemwide efforts aimed at clinical and educational collaboration and oversees the Partners research enterprise of more than $1.8 billion annually. As Chief Academic Officer, Dr. Klibanski has management responsibilities for personalized medicine; Partners Clinical Trials Office; Partners Innovation which includes commercialization and licensing; research data science/digital health and research subject protection as well as graduate medical education and continuing professional development. Dr. Klibanski is also the Chief of Neuroendocrine at MGH and is recognized internationally for her high impact research in neuroendocrine disorders and pituitary tumors.
“Anne is one of our most experienced senior leaders as well as a distinguished clinician, researcher and teacher. She has broad responsibility for many of our key missions and is a proven leader and manager of complex efforts with extensive experience overseeing large clinical and executive teams, crafting a systemwide approach to future state radiology, pathology and anesthesiology structure and investments,” said Scott Sperling, Chair of the Partners Board of Directors. “Anne will work closely with hospital presidents, clinicians, researchers and administrative leadership to guide important systemwide initiatives such as Partners 2.0.”
“We have a strong team of more than 74,000 committed employees across our system, all working to provide outstanding patient care, develop innovative health care solutions, and improve the quality of life for those living in the communities where our patients live and work,” said Dr. Klibanski. “I look forward to guiding Partners through this important transition as we chart our course for Partners’ future.”
Dr. Klibanski received her B.A., magna cum laude with honors in literature from Barnard College and her M.D. from New York University Medical Center. She is the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School and an Academic Dean for Partners at Harvard Medical School. Dr. Klibanski is a recognized expert in the field of translational research focusing on rare endocrine diseases and serves on the MGH General Executive Committee, the Board of Albireo Pharmaceuticals, Scientific Advisory Board of Crinetics and the Board of Partners International.
She is an elected member of the Association of American Physicians and the American Society of Clinical Investigation; recipient of the Clinical Endocrinology Trust Medal – British Endocrine Society and the Endocrine Society Clinical Investigator Award.
This month, Dr. Klibanski was recognized by Modern Healthcare as one of 2019’s Top 25 Women Leaders in health care.
The timeline for naming a permanent CEO is expected take up to one year.